TIBs bearing KRAS-specific BCRs could represent the cross-activation of the humoral immune response in patients with KRAS-mutant cancer the same way as the NY-ESO-1 paradigm in melanoma (12, 13, 16, 17, 25, 49, 50). Here, KRAS is linked to cancer.